The estimated Net Worth of Michael W Aguiar is at least 19.2 百万$ dollars as of 4 December 2017. Michael Aguiar owns over 12,022 units of Innoviva Inc stock worth over 19,029,596$ and over the last 9 years Michael sold INVA stock worth over 157,849$.
Michael has made over 1 trades of the Innoviva Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Michael sold 12,022 units of INVA stock worth 157,849$ on 4 December 2017.
The largest trade Michael's ever made was selling 12,022 units of Innoviva Inc stock on 4 December 2017 worth over 157,849$. On average, Michael trades about 925 units every 0 days since 2016. As of 4 December 2017 Michael still owns at least 980,907 units of Innoviva Inc stock.
You can see the complete history of Michael Aguiar stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 951 GATEWAY BOULEVARD, , SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Innoviva Inc have traded over 394,127,811$ worth of Innoviva Inc stock and bought 682,000 units worth 8,768,520$ . The most active insiders traders include Plc Gsk、Alexander J Sarissa Capital...、Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of 18,199,955$. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth 153,806$.
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
Innoviva Inc executives and other stock owners filed with the SEC include: